Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

1. Rational Every year, around 5,000 people in Sweden are diagnosed with malignant skin melanoma. In the early stages of malignant skin melanoma, the chance of cure with surgery is very good. At a later stage, when the melanoma has become thick and/or has spread, the risk of recurrence is greater despite radical surgery. Therefore, in these cases (even in cases of recurrence after radical surgery), additional treatment with immunotherapy is often given, as it has been shown to reduce the risk of recurrence. Immunotherapy is given for one year based on previous research studies, but it has not

Trial Details

NCT ID
NCT06488482
Phase
PHASE3
Sponsor
Uppsala University
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • nivolumab or pembrolizumab
Locations (sample)
  • Helsinki, Finland|60.16952,24.93545
  • Kuopio, Finland|62.89238,27.67703
  • Tampere, Finland|61.49911,23.78712
  • Turku, Finland|60.45148,22.26869
  • Ålesund, Norway|62.47225,6.15492

Key Eligibility Criteria

  • Provision of written informed consent for participation.
  • ≥ 18 years of age.
  • Performance status ECOG/WHO 0-1.
  • Adequate organ functions as per standards for immunotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →